Pharmacy Market BUZZ

Market News, Products, Services, and Trends

BD Nano™ 2nd Gen Pen Needles by embecta: Redesigned With Patients in Mind

To develop and provide solutions that make life better for people living with diabetes.

Company Background

embecta is one of the largest pure-play diabetes care companies in the world following its spinoff from Becton, Dickinson and Company (BD) on April 1st, 2022. The company’s history in the diabetes care category dates back to 1924 and the development of the world’s first specialized insulin syringe. Today, it is the leading producer of diabetes injection devices, manufacturing approximately 8 billion injection devices annually for an estimated 30 million patients. embecta empowers people with diabetes to live their best life through innovative solutions, partnerships, and the passion of more than 2,000 employees around the globe.

Product Overview

When it comes to managing diabetes with insulin, a comfortable injection experience matters. BD Nano™ 2nd Gen Pen Needles can help patients inject with more comfort and confidence.

Patented features include:

• Wider outer cover for easier attachment to pen device.

• Larger, green, inner needle shield for easier grip and removal before an injection.

• Contoured needle base that provides greater comfort and compensates for injection force variability, supporting more reliable subcutaneous injections.

The unique features of BD Nano™ 2nd Gen 4 mm Pen Needles offer a number of potential benefits, including:

• Reduction in injection pain.

• Less force required to deliver the full dose.

• Greater confidence that the full dose has been delivered compared to other pen needles studied.

BD Nano™ 2nd Gen Pen Needles are:

• Compatible with widely used pen injection devices.

• Covered by most health plans at the preferred co-pay, including Medicare Part D.

Not all patients inject the same. Some may apply excessive force, which can increase the risk of injecting deeper than intended, increasing the risk of intramuscular (IM) injections. Shorter needles (i.e. 4 mm pen needles) may lower the risk of inadvertent IM injection, which is associated with unpredictable insulin absorption and variable effects on glucose. Educating patients on structured injection technique can help improve glycemic control. A few steps to deliver structured injection technique training include using a new needle with every injection, rotating injection sites, and injecting within sites at least one finger width apart, and shifting to short needle lengths.9 Join the movement and help ensure your patients have enough pen needles or insulin syringes to use a new needle with each injection.

Today's Posts